Trial Profile
A Phase I, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Nebulized, TRN-157 Inhalation Solution in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2014
Price :
$35
*
At a glance
- Drugs TRN 157 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Theron Pharmaceuticals
- 30 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 14 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 13 May 2014 New trial record